Company Overview - Ekso Bionics focuses on developing exoskeleton solutions to enhance human strength, endurance, and mobility[6] - The company has deployed over 900 devices in more than 450 centers worldwide[7, 12, 37] Financial Performance & Market Opportunity - In 2023, Ekso Bionics generated $15.4 million in clinical revenue[6] - The company is targeting positive operating cash flow through revenue growth and improved efficiencies[7, 71] - The total potential addressable market for personal mobility exoskeletons in the USA is estimated at ~$34 billion, including potential future neurodegenerative indications and general debility usage[55] Reimbursement & Market Access - CMS reimbursement for Ekso Indego Personal is established at $91,000, effective April 1, 2024[7, 50] - CMS & VA covered individuals with SCI is ~176,000[52] - The company is leveraging clinical relationships and partnerships for efficient market access[56, 57] Product Portfolio - The company offers a range of products, including EksoNR and Ekso Indego Therapy for neuro-rehabilitation[6] - Ekso is developing the Nomad device, with a limited research release in 2024 and commercial release expected in 2025[24] - EVO is an upper body exoskeleton for industrial applications, with a potential market opportunity > $8 billion annually[60, 66]

As filed with the Securities and Exchange Commission on August 28, 2024. Registration No. 333-281081 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S‑1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 EKSO BIONICS HOLDINGS, INC. (Exact name of Registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Mark B. Baudler Austin D. March Wilson Sonsini Goodr ...